 Legend Biotechs Carvykti was approved this year for the treatment of fourth and fifth-line-plus multiple myeloma. Carvykti is partnered with JJ, and the launch is off to a strong start despite supply challenges, thanks to the outstanding CARTITUDE-1 trial data. 